As of December 15, 2025, Blueprint Medicines Corp has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $129.46, this represents a potential upside of -130.2%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -126.3% |
| Potential Upside (10-year) | -130.2% |
| Discount Rate (WACC) | 6.0% - 9.0% |
Revenue is projected to grow from $509 million in 12-2024 to $1483 million by 12-2034, representing a compound annual growth rate of approximately 11.3%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 509 | 104% |
| 12-2025 | 594 | 17% |
| 12-2026 | 666 | 12% |
| 12-2027 | 750 | 13% |
| 12-2028 | 847 | 13% |
| 12-2029 | 945 | 12% |
| 12-2030 | 1074 | 14% |
| 12-2031 | 1159 | 8% |
| 12-2032 | 1254 | 8% |
| 12-2033 | 1367 | 9% |
| 12-2034 | 1483 | 8% |
Net profit margin is expected to improve from -13% in 12-2024 to -12% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (67) | -13% |
| 12-2025 | (75) | -13% |
| 12-2026 | (83) | -12% |
| 12-2027 | (92) | -12% |
| 12-2028 | (103) | -12% |
| 12-2029 | (113) | -12% |
| 12-2030 | (128) | -12% |
| 12-2031 | (138) | -12% |
| 12-2032 | (149) | -12% |
| 12-2033 | (162) | -12% |
| 12-2034 | (176) | -12% |
with a 5-year average of $7 million. Projected CapEx is expected to maintain at approximately 3% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 10 |
| 12-2026 | 13 |
| 12-2027 | 15 |
| 12-2028 | 17 |
| 12-2029 | 21 |
| 12-2030 | 24 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 62 |
| Days Inventory | 587 |
| Days Payables | 127 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 9M/2025 | (25) | (0) | 12 | 33 | (70) |
| 2026 | (34) | (0) | 18 | 9 | (61) |
| 2027 | (36) | (0) | 21 | 7 | (64) |
| 2028 | (40) | (0) | 23 | 26 | (88) |
| 2029 | (41) | (1) | 26 | 16 | (82) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -126.3% |
| 10-Year DCF (Growth) | 0.00 | -130.2% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Blueprint Medicines Corp (BPMC) a buy or a sell? Blueprint Medicines Corp is definitely a sell. Based on our DCF analysis, Blueprint Medicines Corp (BPMC) appears to be overvalued with upside potential of -130.2%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $129.46.